Year | Fixed effects | Random effects |
---|---|---|
Reference case: RCTs with 100% HER2+ patients and HER2+ subgroups | ||
2008 | DIC = 1.69 TotResDev = 2.99 vs. 4 | DIC = 3.19 TotResDev = 3.74 vs. 4 Heterogeneity SD (95% CI) = 0.68 (0.01 to 4.55) |
2010 | DIC = 17 TotResDev = 10.63 vs. 10 | DIC = 17.96 TotResDev = 9.66 vs. 10 Heterogeneity SD (95% CI) = 0.37 (0.02 to 2.41) |
2012 | DIC = 28.67 TotResDev = 19.63 vs. 16 | DIC = 26.29 TotResDev = 14.64 vs. 16 Heterogeneity SD (95% CI) = 0.31 (0.05 to 1.16) |
2014 | DIC = 25.24 TotResDev = 25.67 vs. 25 | DIC = 25.76 TotResDev = 23.27 vs. 25 Heterogeneity SD (95% CI) = 0.12 (0.01 to 0.43) |
2016 | DIC = 28.17 TotResDev = 33.94 vs. 34 | DIC = 28.17 TotResDev = 32.07 vs. 34 Heterogeneity SD (95% CI) = 0.08 (0.01 to 0.27) |